Durham immunotherapy company Dualogics has entered into a collaboration agreement with South Korea’s Y-Biologics to use their combined expertise to discover and develop novel cancer antibodies.
Read More
Immunotherapy is a treatment approach that harnesses certain parts of the body’s own immune system to target and attack a disease, such as cancer. This approach can come in many forms and can be administrated through injections, pills or capsules, topical ointments or creams, or a catheter.
Read More
Following up on its recent multi-billion-dollar acquisition of cancer-focused drug firm Tesaro, GlaxoSmithKline on Tuesday announced a deal worth more than $4 billion to develop an immunotherapy targeting cancer.
Read More
Grid Therapeutics, a Durham-based biotechnology company developing the first human derived targeted immunotherapy for cancer, has raised more than $4.5 million of a $5 million equity offering, according to a filing with the U.S. Securities and Exchange Commission.
Read More
Scientists at the University of North Carolina School of Medicine and North Carolina State University have created an injectable gel-like scaffold that can hold a combination of chemo and immunotherapeutic drugs and deliver them locally to tumors. Researchers say the approach may “Beat back tumor development with limited side-effects.”
Read MoreArgos Therapeutics, an immune-oncology company, has enough cash to to fund its operations through the end of 2018, according to a securities filing.
Read More
